Fundraising FoxSofinnova Ventures — 2025 Investments
6 investments dated 2025 · listed companies and verified rows first · show all
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in
Board seatDavid Kabakoff· per SEC Form D
Co-investorsBay City CapitalCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan Capital+4 more
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.
BiotechBerkeley, US
Allison J. Hulme(CEO & President)inJohn Kincaid(Chief Scientific Officer)inDavis Ryman(Executive Officer)inMicah Zajic(Executive Officer)inIan Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)
Board seatLars Ekman· per SEC Form D
Co-investorsCoastCapCTI Life Sciences Fund L.P.Felix JahnFJ LabsLuma GroupvenBio Partners+2 more
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Board seatMaha Katabi· per SEC Form D
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesViking GlobalWestlake Village BioPartners+11 more
ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.
BiotechHealthtechMedical DevicesOslo, NO
Roy Larsen(Scientific Co-Founder)Øyvind Bruland(Scientific Co-Founder; SAB Chairman)Margaret Yu(Chief Medical Officer)inPhilippe Dasse(Chief Technical Officer)inAmra Demirovic(Chief Human Resources Officer)inNicole Hadas(Chief Legal Officer)
Co-investorsB Capital GroupB4 CapitalF-Prime CapitalAlexandriaB CapitalOmega Funds+2 more
.jpeg){kind=logo}
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Atsena Therapeutics, Inc.Cleveland Diagnostics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.